Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001136
UniProt IDP22102
Primary gene name(s)GART
Synonym gene name(s)PGFT, PRGS
Protein nameTrifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase
Protein functionunknown
Subcellular locationunknown
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P22102
Gene Ontology
(Biological Process)
Complete annatation
'de novo' IMP biosynthetic process [GO:0006189];
brainstem development [GO:0003360];
cerebellum development [GO:0021549];
cerebral cortex development [GO:0021987];
glycine metabolic process [GO:0006544];
purine nucleobase biosynthetic process [GO:0009113];
purine ribonucleoside monophosphate biosynthetic process [GO:0009168];
response to inorganic substance [GO:0010035];
response to organic substance [GO:0010033];
tetrahydrofolate biosynthetic process [GO:0046654]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
metal ion binding [GO:0046872];
phosphoribosylamine-glycine ligase activity [GO:0004637];
phosphoribosylformylglycinamidine cyclo-ligase activity [GO:0004641];
phosphoribosylglycinamide formyltransferase activity [GO:0004644]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
extracellular exosome [GO:0070062]
Protein-protein interaction108888
Phylogenetic treeP22102
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD32.02483011890142.44255227155321e-093.24068202789173e-08
AZA vs. DISU-0.4135788711779930.1033363773831470.64742001358003
AZA vs. IL70.3839344533466430.04621577411115490.639827379000638
AZA vs. SAHA-0.303043346907660.2148145531856480.583128862726535
DISU vs. CD3-2.451219333319041.43745793046435e-103.4069561075188e-09
DISU vs. IL70.788598309412630.001906556996968960.0411178064796953
DISU vs. SAHA0.1118619619145990.7016496006592460.911382414772028
DMSO vs. AZA-0.01264224486922460.9399505485561441
DMSO vs. CD3-2.050321472591926.4106597807978e-108.58458574201946e-09
DMSO vs. DISU0.3987733456816750.1033836321648280.575541683311401
DMSO vs. IL70.4039236841164130.02496533980861430.321809580752529
DMSO vs. SAHA-0.2967600439401050.2087145897808790.549919157795039
HIV vs. Mock in Activation-0.1028273229126450.8685484293212310.999983755607037
HIV vs. Mock in Latency-0.1921780029367010.2458485194151470.999834320637052
IL7 vs. CD3-1.632781240749766.85338732209217e-076.95162228168879e-06
SAHA vs. CD3-2.352671612478222.17749263065059e-104.26720597449992e-09
SAHA vs. IL7-0.6903283903867420.004779671572435860.0371801593753206
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
-0.3779 0.03783

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change -1.652728669
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.22793 0.104803
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
0.032 6.75E-04

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.971 0.986 0.97 0.91 0.938
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
212378_at 1.42 No upregulated in CD8+ cells
212379_at 1.68 No upregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00642 Pemetrexed approved, investigational yes inhibitor
DB02236 Glycinamide Ribonucleotide experimental unknown unknown
DB03546 10-CF3C(OH)2-DDACTHF experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1MEJ X-ray 2.0Å A/B/C=810-1010.
1MEN X-ray 2.2Å A/B/C=810-1010.
1MEO X-ray 1.7Å A=808-1010.
1NJS X-ray 1.9Å A/B=808-1010.
1RBM X-ray 2.3Å A/B=808-1010.
1RBQ X-ray 2.1Å A/B/C/D=808-1010.
1RBY X-ray 2.1Å A/B/C/D=808-1010.
1RBZ X-ray 2.1Å A/B=808-1010.
1RC0 X-ray 2.0Å A/B=808-1010.
1RC1 X-ray 2.2Å A/B=808-1010.
1ZLX X-ray 2.2Å A=808-1010.
1ZLY X-ray 2.0Å A=808-1010.
2QK4 X-ray 2.4Å A/B=1-430.
2V9Y X-ray 2.1Å A/B=467-794.
4EW1 X-ray 1.5Å A=810-1010.
4EW2 X-ray 1.6Å A=808-1010.
4EW3 X-ray 1.7Å A=808-1010.
4ZYT X-ray 1.7Å A=808-1010.
4ZYU X-ray 1.9Å A=808-1010.
4ZYV X-ray 2.0Å A=808-1010.
4ZYW X-ray 2.0Å A=808-1010.
4ZYX X-ray 1.6Å A=808-1010.
4ZYY X-ray 1.8Å A=808-1010.
4ZYZ X-ray 1.6Å A=808-1010.
4ZZ0 X-ray 1.6Å A=808-1010.
4ZZ1 X-ray 1.3Å A=808-1010.
4ZZ2 X-ray 1.4Å A=808-1010.
4ZZ3 X-ray 2.5Å A=808-1010.
5J9F X-ray 2.1Å A=808-1010.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00230 Purine metabolism - Homo sapiens (human)
hsa00670 One carbon pool by folate - Homo sapiens (human)
hsa01100 Metabolic pathways - Homo sapiens (human)
hsa01523 Antifolate resistance - Homo sapiens (human)